Table 2

Cardiorespiratory and Muscular Results Before and After 3 Months of Testosterone Supplementation Therapy

Testosterone Group (n = 31)Placebo Group (n = 33)Changes (Δ)
BeforeAfterBeforeAfterTestosteronePlacebo
BMI, kg/m226.4 ± 3.728.7 ± 4.326.1 ± 4.426.6 ± 3.62.4 ± 0.20.5 ± 0.06
Body weight, kg63.5 ± 13.766.8 ± 11.464.7 ± 8.365 ± 12.90.5 ± 0.020.3 ± 0.02
SBP, mm Hg125.6 ± 6.2121.3 ± 42.7128.2 ± 46.3125.0 ± 37.9−3.3 ± 1.2−3.2 ± 0.9
DBP, mm Hg92 ± 13.080 ± 12.089 ± 11.783 ± 11.7−12 ± 3.0−6.4 ± 1.7
Resting HR, beats/min74.3 ± 7.270 ± 11.577.6 ± 8.271.4 ± 8.7−4.3 ± 1.8−3.2 ± 1.2
Peak VO2, ml/kg/min13.4 ± 4.416.3 ± 1.713.8 ± 3.214.1 ± 3.62.9 ± 0.80.3 ± 0.07
VE/VCO2slope33.6 ± 7.029.2 ± 5.134.1 ± 9.532.6 ± 8.8−4.4 ± 1.0−1.5 ± 0.4
Peak workload, W78.3 ± 16.088.2 ± 18.777.3 ± 14.274.3 ± 18.09.9 ± 2.42.0 ± 0.7
6MWT, m386.6 ± 121.0472.8 ± 138.4390.9 ± 107.4428.2 ± 112.086.2 ± 14.537.3 ± 8.7
MVC, Nm116.7 ± 26.3135.6 ± 21.2116.7 ± 26.3119.7 ± 26.318.9 ± 3.33.0 ± 1.1
PTmax, Nm74.0 ± 17.483.4 ± 16.374.2 ± 14.476.3 ± 19.29.6 ± 1.22.1 ± 0.5
EF, %31.5 ± 9.932.1 ± 7.233.8 ± 6.532.8 ± 10.40.6 ± 0.04−1.0 ± 0.03
LVEDD, mm68 ± 35.766.9 ± 23.267.3±27.266.8 ± 25.4−1.1 ± 0.030.5 ± 0.03

Data are expressed as mean ± SD.

6MWT = 6-min walking test; BMI = body mass index; DBP = diastolic blood pressure; EF = ejection fraction; HR = heart rate; LVEDD = left ventricular end-diastolic diameter; MVC = maximal voluntary contraction; Nm = Newton meter; PTmax = isokinetic power torque; SBP = systolic blood pressure; VE/VCO2= ventilation/carbon dioxide output; VO2= oxygen consumption.

  • Within groups differences;

  • between groups differences at p < 0.05.